Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (21-30 of 302) with videos related to

Pageof 31
Sort By:
Bulletin Du Cancer|November 6, 2007
[Targeting ErbB receptors in breast cancer]Pierre Fumoleau, Mario Campone, Bruno Coudert, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 22, 2020
Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancerElie Dagher, Laura Simbault, Jérôme Abadie, et al.
Bulletin Du Cancer|December 31, 2021
Amélie Mallet, De Calbiac Ombline, Marie Robert, et al.
Human Pathology|March 28, 2006
Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization studyDelphine Loussouarn, Jacques Brunon, Hervé Avet-Loiseau, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapyBéatrice Clémenceau, Géraldine Gallot, Régine Vivien, et al.
Expert Opinion on Investigational Drugs|April 12, 2017
Olaparib for the treatment of breast cancerMarie Robert, Jean-Sébastien Frenel, Carole Gourmelon, et al.
Cancer Management and Research|June 14, 2019
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new dataPauline du Rusquec, Ombline de Calbiac, Marie Robert, et al.
Expert Opinion on Emerging Drugs|September 26, 2018
Emerging PARP inhibitors for treating breast cancerMarie Robert, Anne Patsouris, Jean-Sébastien Frenel, et al.
Expert Opinion on Pharmacotherapy|August 4, 2016
Vinflunine for the treatment of breast cancerCarole Gourmelon, Héloïse Bourien, Paule Augereau, et al.
International Journal of Environmental Research and Public Health|January 21, 2023
Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer CentersFrançois Bocquet, Judith Raimbourg, Frédéric Bigot, et al.
Pageof 31

Showing results (21-30 of 302) with videos related to

Sort By:
Pageof 31
Bulletin Du Cancer|November 6, 2007
[Targeting ErbB receptors in breast cancer]Pierre Fumoleau, Mario Campone, Bruno Coudert, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 22, 2020
Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancerElie Dagher, Laura Simbault, Jérôme Abadie, et al.
Bulletin Du Cancer|December 31, 2021
Amélie Mallet, De Calbiac Ombline, Marie Robert, et al.
Human Pathology|March 28, 2006
Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization studyDelphine Loussouarn, Jacques Brunon, Hervé Avet-Loiseau, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapyBéatrice Clémenceau, Géraldine Gallot, Régine Vivien, et al.
Expert Opinion on Investigational Drugs|April 12, 2017
Olaparib for the treatment of breast cancerMarie Robert, Jean-Sébastien Frenel, Carole Gourmelon, et al.
Cancer Management and Research|June 14, 2019
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new dataPauline du Rusquec, Ombline de Calbiac, Marie Robert, et al.
Expert Opinion on Emerging Drugs|September 26, 2018
Emerging PARP inhibitors for treating breast cancerMarie Robert, Anne Patsouris, Jean-Sébastien Frenel, et al.
Expert Opinion on Pharmacotherapy|August 4, 2016
Vinflunine for the treatment of breast cancerCarole Gourmelon, Héloïse Bourien, Paule Augereau, et al.
International Journal of Environmental Research and Public Health|January 21, 2023
Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer CentersFrançois Bocquet, Judith Raimbourg, Frédéric Bigot, et al.
Pageof 31